Login / Signup

Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.

William A FahyFarshid Homayoun-ValianiAnthony CahnJon RobertsonAlison TempletonWilhelmine H MeerausRobert WilsonMike LowingsMiriam MarottiSarah L WestMaggie TabbererEdith M Hessel
Published in: International journal of chronic obstructive pulmonary disease (2021)
The addition of nemiralisib to standard-of-care treatment for 12 weeks did not improve lung function or re-exacerbations in patients with, and following an acute exacerbation of COPD. However, this study demonstrated that large clinical trials recruiting acutely exacerbating patients can successfully be conducted.
Keyphrases